OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas	50
MLL-Rearranged Acute Lymphoblastic Leukemia	47
IDH Inhibitors in AML—Promise and Pitfalls	32
Extramedullary Disease in Multiple Myeloma	32
MRD Assessment in Multiple Myeloma: Progress and Challenges	27
Artificial Intelligence in Hematology: Current Challenges and Opportunities	27
Management of Ibrutinib Toxicities: a Practical Guide	24
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib	20
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments	20
Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults	18
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia	17
Treatment-Free Remission: the New Goal in CML Therapy	16
Enteropathy-Associated T cell Lymphoma	16
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review	15
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms	14
Thrombocytosis and Thrombosis: Is There Really a Correlation?	14
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders	13
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	13
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	13
Future Directions in Chronic Phase CML Treatment	12
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	12
Supportive Care in Multiple Myeloma	12
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities	11
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding	11
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches	11

Molecular Pathogenesis of Myeloproliferative Neoplasms	11
Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges	11
Polatuzumab Vedotin: a New Target for B Cell Malignancies	11
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma	10
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	10
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects	10
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	10
Updates in the Diagnosis and Management of AL Amyloidosis	9
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options	9
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit	9
Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath	9
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	8
Antibody-Based Treatment Approaches in Multiple Myeloma	8
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia	8
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?	8
Advances in Supportive Care for Acute Lymphoblastic Leukemia	8
Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies	7
Management of Chronic Myeloid Leukemia in Children and Young Adults	7
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	7
Radiogenomics and Its Role in Lymphoma	7
BTK Inhibitors in Chronic Lymphocytic Leukemia	7
The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond	7
Treatment of Aggressive B Cell Lymphomas: Updates in 2019	7
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?	7
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies	6
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	6
MRD in ALL: Optimization and Innovations	6
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra	6
Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome	6
Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy	6
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms	6
NPM1 Biology in Myeloid Neoplasia	6
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management	6
Targeting BCMA in Multiple Myeloma	6
The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition	6
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine	5
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms	5
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents	5
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma	5
Choosing Wisely® in Hematology: Have We Made a Difference?	5
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings	5
Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?	5
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic	5
Immunodeficiency-Related Lymphoid Proliferations: New Insights With Relevance to Practice	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	4
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma	4
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities	4
Myeloproliferative Neoplasms with Monocytosis	4
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job	4
Editing of Endogenous Genes in Cellular Immunotherapies	4

Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia	4
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma	3
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	3
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses	3
New Approaches to Treating Challenging Subtypes of ALL in AYA Patients	3
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera	3
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	3
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	3
Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm	3
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma	3
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	3
Bispecific Antibodies for the Treatment of Multiple Myeloma	3
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	3
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery	3
Precision Medicine in Myeloid Malignancies: Hype or Hope?	3
Progress in the Management of Smoldering Multiple Myeloma	3
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	3
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	3
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions	3
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia	3